Discovery. Diagnostics. Delivery.

Can be accessed on our Customer Learning Portal. The e-learning courses offer detailed and solution focused training to help better understand how to solve for common scenarios.

THE DIFFERENCE OF ONE LESS COMPLICATION

With a powerful partner in the new BD.

Industry leaders BD and Bard are joining forces to help you fight IV-related complications. From failed catheter placements to bloodstream infections, IV-related complications are dangerous and costly. But they’re also preventable.

Uscid est ad quis et lam sitatium commoloribus solupta illaborum doloria alisci dioribus si quis porereh enianimus mollam, quo maxim quis ma senimus, alit,Deles etusapici am, inusdae commodi cupiderro doluptas acipsap elignatio omnihilla inihiliciu Denihit doluptamus ut ped ut eatinie ndandem. Quae. Olut exerios dipsum nis

Discovery. Diagnostics. Delivery.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Archit eos desgad eici omnit adias dis arcieni hilli perovit o c test eumquiam adi voluptias

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Pellentesque habitant morbi tristique senectus et netus

Play

35–50% of peripheral IVs don't meet their intended target

Unnecessary complications, such as infections, occlusions, phlebitis, dislodgement and infiltration/extravasation, are a large cause for 35–50% of peripheral IVs failing.1

$45,814 per CLABSI

Every year, 82,000 patients in the U.S. acquire a central line-associated blood stream infection (CLABSI)2, costing hospitals $45,814 on average per patient occurrence.3

Up to 36% of central venous catheters occlude

CVAD occlusions occur in up to 36% of central venous catheters in the U.S.4 Post occlusion costs can be up to $2,458 per patient occurrence.5

Used by more than 1000 oncology facilities

BD offers a complete closed system drug transfer device (CSTD) portfolio to help reduce the risk of staff exposure to hazardous drugs.

Placeholder

Pellentesque habitant morbi

  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada

Placeholder

Pellentesque habitant morbi

  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada
  • Tristique senectus et netus et malesuada

Placeholder

BD Vascular Access Management is an integrated approach to total vascular access care where we work closely with you to help reduce the risk of IV-related complications over the life of each line in your facility.

Placeholder

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Webcasts

Join us every 2nd Tuesday and 4th Thursday of the month
at 11:00 a.m. PT / 2:00 p.m. ET

Register Now

Store Tab

360° rotation knob is effectively sized, contoured and located to enable easy instrument rotation.

360° rotation knob is effectively sized

360° rotation knob is effectively sized

360° rotation knob is effectively sized

More product details

Hospitals and healthcare facilities

BD is a market leader in hospital products that can reduce the incidence of sharps injuries and exposure to bloodborne pathogens. Patient safety has been a focus of BD innovation for years, not only in the United States but also around the world. Working closely with organizations like the International Safety Center (EPINet) is an important part of our efforts to keep patients and workers safe.

Safety syringes and needles >>
Hazardous drug safety >>
Infection prevention >>

Hospitals and healthcare facilities

BD is a market leader in hospital products that can reduce the incidence of sharps injuries and exposure to bloodborne pathogens. Patient safety has been a focus of BD innovation for years, not only in the United States but also around the world. Working closely with organizations like the International Safety Center (EPINet) is an important part of our efforts to keep patients and workers safe.

Safety syringes and needles >>
Hazardous drug safety >>
Infection prevention >>

Clinical assessments to establish a baseline and to align with best practices

BD experts use proprietary tools to baseline all vascular access practices across your care settings

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Pellentesque habitant morbi tristique senectus et netus et malesuada fames ac turpis egestas vestibulum tortor quam.

Let's have a conversation

BD VAM has already been proven to work*, delivering a 32% reduction in overall complications5 and a 12% reduction in costs6

VAM case study - University of Kansas                    VAM case study - University of Florida

Learn about BD's success in helping Kansas and Florida Hospitals reduce vascular access complications

Let's have a conversation

REFERENCES

1. Helm RE, Klausner JD, Klemperer JD, Flint LM, Huang E. Accepted but unacceptable: peripheral IV catheter failure. J Infus Nurs. 2015;38(3):189–203.

2. Vital signs: central line-associated blood stream infections. Centers for Disease Control and Prevention (CDC) website. https://www.cdc.gov/vitalsigns/pdf/2011-03-vitalsigns.pdf Published March 1, 2011. Accessed October 18, 2017.

3. Zimlichman E, Henderson D, Tamir O, et al. Health care-associated infections A meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med. 2013;173(22):2039–2046.

4. Krzywda EA. Predisposing factors, prevention, and management of central venous catheter occlusions. J Intraven Nurs. 1999;22(6):S11–S17.

5. Ernst FR, Chen E, Lipkin C, Tayama D, Amin AN. Comparison of Hospital Length of Stay, Costs, and Readmissions of Alteplase Versus Catheter Replacement Among Patients With Occluded Central Venous Catheters. J Hosp Med. May 2014; 9(8):490–496.

6 Pittenger C. Navigating Change to Improve Outcomes in Peripheral Vascular Access: A Collaborative Approach. Report presented at: AVA Annual Conference; 2017; Phoenix, AZ

* Single center study. Outcomes may vary for different institutions.